Health Care/Hospital
Road to G20 Presidency, Indonesia Will Employ the Health Bubble System during the Event
JAKARTA, Indonesia, March 14, 2022 /PRNewswire/ -- On track to host the G20 summit inBali on November 15-16, The Indonesia's Ministry of Health is set to implement a strict health protocol system as a precaution against COVID-19. The system will serve as a guideline for every in-person activity d...
2022-03-14 20:03
2040
NuclixBio Announces a Collaborative Research Agreement with PharmAbcine
SEOUL, South Korea, March 14, 2022 /PRNewswire/ -- NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech...
2022-03-14 20:00
1935
111, Inc. Becomes First Online Retail Platform for BGI's SARS-CoV-2 Virus Antigen Detection Kits
SHANGHAI, March 14, 2022 /PRNewswire/ -- On March 14, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company signed a strategic cooperation agreement with Shenzhen BGI Co., Ltd. (SZ: 300676) under which BGI will supply its SARS-CoV-2 Virus Ant...
2022-03-14 19:35
1814
Hexvix® Has Obtained CDE Approval for the Inclusion In the Clinical Real-world Evidence Pilot Study
SHANGHAI, March 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that the Hainan Provincial Medical Products...
2022-03-14 14:25
1558
Impact Therapeutics Announces Completion of Series D1 Financing
SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D1 financing. Institutional investors that par...
2022-03-14 12:43
1865
Happiness Development Announces $6.7 Million Registered Direct Offering To Support Its Auto Business
NANPING, China, March 11, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) an emerging and diversified company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce sales and e-commerce marketing sol...
2022-03-11 21:00
5639
CYMBIOTIKA EXPANDS PRODUCT OFFERINGS IN AUSTRALIAN MARKET
Top nutritional supplement brand widens access to holistic wellness with eight new products on recently launched Australian site SAN DIEGO, March 11, 2022 /PRNewswire/ -- Cymbiotika, a leading nutritional supplement brand known for creating pure, clinically-backed supplements, today announced th...
2022-03-11 05:26
2027
THE WORLD'S FIRST ACADEMIC PAPER ON THE POTENTIAL USE OF VIRTUAL REALITY IN MODULATING PSYCHEDELIC-ASSISTED PSYCHOTHERAPY PUBLISHED BY THE CO-FOUNDERS OF ENOSIS THERAPEUTICS
The Peer-Reviewed Article Published In Volume 13 March 2022 Issue Of Frontiers In Psychology Journal Is A Landmark Examination Of Virtual Reality Therapy Combined With Psychedelic Therapy. MELBOURNE, Australia, March 10, 2022 /PRNewswire/ -- The world's first scientific paper offering a careful...
2022-03-10 21:00
1695
Pulnovo Medical Appoints Ms. Jessie Lian Jia as New CEO
SHANGHAI, March 10, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally
recognized OTM innovative platform, recently announced the appointment of Ms.
Jessie Lian Jia as Chief Executive Officer and Executive Director of the Board.
2022-03-10 20:00
2533
Artificial Retinal Device Mimics Human Optical Illusions: WPI-MANA
TSUKUBA, Japan, March 10, 2022 /PRNewswire/ -- A team at the International Center for Materials Nanoarchitectonics (WPI-MANA) has developed the first-ever artificial retinal device that increases the edge contrast between lighter and darker areas of an image, using ionic migration and interaction...
2022-03-10 16:00
1477
Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the AACR 2022 Annual Meeting
* The abstract of BBT-207 pre-clinical studies is now available at the AACR website * Preclinical data suggests that BBT-207 may have the potential to be positioned as a frontline treatment with the anti-tumor effects in EGFR mutant NSCLC SEONGNAM, South Korea, March 9, 2022 /PRNewswire/ -- B...
2022-03-10 07:00
1634
English Version of Hands-On Medical VR Developed. Exhibiting At SXSW 2022.
TOKYO, March 9, 2022 /PRNewswire/ -- Jolly Good Inc. (based in Chuo-ku, Tokyo, Japan; CEO: Kensuke Joji; hereafter "Jolly Good"), known for developing and providing medical VR solutions and digital therapeutics VR programs, has developed an English version of their VR medical hands-on tracking ...
2022-03-09 21:00
1504
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational r...
2022-03-09 21:00
1714
Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
SUZHOU, China and ROCKVILLE, Md., March 8, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of t...
2022-03-09 07:47
3403
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
SEATTLE, Wash. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- ProfoundBio announced that preclinical data from its pipeline of novel, proprietary antibody-drug conjugates (ADCs) and technology will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held Apr...
2022-03-09 06:58
4524
Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022
Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage...
2022-03-09 05:30
1869
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
HONG KONG, March 7, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved the IND...
2022-03-08 11:49
1754
World Alliance for Mercury-Free Dentistry announces: Nonprofit groups from 48 countries call for VIC-based Southern Dental Industries to exit selling mercury fillings to 'lower soci-economic markets'
WASHINGTON, March 8, 2022 /PRNewswire/ -- Alarmed that Victoria-based Southern Dental Industries intends to keep selling mercury fillings (dental amalgam) to 'lower soci-economic markets' rather than its supply of non-polluting alternatives, 64 civil society organisations from 48 nations call on ...
2022-03-08 08:27
1557
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies
PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manu...
2022-03-08 08:00
1540
Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases
* The company reinforces its strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) * Through the option-to-license agreement, Bridge will develop a novel anti-fibrotic ion channel modulator, which is a preclinical candidate SEONGNAM, South Korea, March 7, 2022 /PR...
2022-03-08 08:00
1505
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 277 media titles]
2024-11-29 20:33
Most Read
Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
2024-11-26 13:00
5137
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
3902